Tag Archives: Endo Pharmaceuticals

April, 2018

  • 27 April

    Endo to Acquire Specialty Pharmaceutical Company Somerset Therapeutics for $190 Million

    DUBLIN, April 26, 2018 /PRNewswire/ — Endo International plc (NASDAQ: ENDP) today announced that it has reached definitive agreements to acquire Somerset Therapeutics, LLC, a New Jersey based specialty pharmaceutical company that develops and markets sterile injectable and ophthalmic drugs for the U.S. marketplace, and the business of its India based affiliate Wintac Limited, which operates as Somerset Therapeutics’ contract …

June, 2017

  • 9 June

    FDA Requests Removal of Opana ER for Risks Related to Abuse

    Today, the U.S. Food and Drug Administration requested that Endo Pharmaceuticals remove its opioid pain medication, reformulated Opana ER (oxymorphone hydrochloride), from the market. After careful consideration, the agency is seeking removal based on its concern that the benefits of the drug may no longer outweigh its risks. This is …

May, 2015

  • 19 May

    Endo to Acquire Par Pharmaceutical for $8 Billion

    In an effort to boost its generics business, Endo International PLC has agreed to buy Par Pharmaceutical Holdings Inc. for more than $8 billion. The company said that it has entered into a definitive agreement under which it will acquire privately-held Par from TPG in a transaction valued at $8.05 …